Physiomics inks deal to work with Cancer Research UK

12th Oct 2022 12:42

(Sharecast News) - Modelling and simulation-focussed consultancy Physiomics that it has signed an agreement to work with Cancer Research UK, it announced on Wednesday.

The AIM-traded firm said it would use its 'PKPD' modelling capabilities to support the Cancer Research UK-sponsored early phase clinical development of 'ALETA-001' - a CAR-T cell engager candidate for the treatment of blood cancers developed by Aleta Biotherapeutics.

It said the PKPD modelling project was expected to be completed during this calendar year.

"We are delighted to be working with Cancer Research UK, the world's leading cancer charity," said chief executive officer Dr Jim Millen.

"Although we have previously worked with clients whose early clinical trials are sponsored by Cancer Research UK's Centre for Drug Development, this project marks the first occasion on which Physiomics has worked directly with Cancer Research UK."

At 1148 BST, shares in Physiomics were up 26.19% at 2.65p.

Reporting by Josh White at Sharecast.com.